These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16489085)

  • 1. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.
    Hogge DE; Yalcintepe L; Wong SH; Gerhard B; Frankel AE
    Clin Cancer Res; 2006 Feb; 12(4):1284-91. PubMed ID: 16489085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
    Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
    Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity.
    Liu TF; Urieto JO; Moore JE; Miller MS; Lowe AC; Thorburn A; Frankel AE
    Exp Hematol; 2004 Mar; 32(3):277-81. PubMed ID: 15003313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.
    Kim HP; Frankel AE; Hogge DE
    Leuk Res; 2010 Aug; 34(8):1035-42. PubMed ID: 20137810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice.
    Yalcintepe L; Frankel AE; Hogge DE
    Blood; 2006 Nov; 108(10):3530-7. PubMed ID: 16882709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
    Urieto JO; Liu T; Black JH; Cohen KA; Hall PD; Willingham MC; Pennell LK; Hogge DE; Kreitman RJ; Frankel AE
    Protein Expr Purif; 2004 Jan; 33(1):123-33. PubMed ID: 14680969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein.
    Alexander RL; Ramage J; Kucera GL; Caligiuri MA; Frankel AE
    Leuk Res; 2001 Oct; 25(10):875-81. PubMed ID: 11532521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
    Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
    Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias.
    Frankel AE; McCubrey JA; Miller MS; Delatte S; Ramage J; Kiser M; Kucera GL; Alexander RL; Beran M; Tagge EP; Kreitman RJ; Hogge DE
    Leukemia; 2000 Apr; 14(4):576-85. PubMed ID: 10764142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of variant diphtheria toxin-interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials.
    Su Y; Li SY; Ghosh S; Ortiz J; Hogge DE; Frankel AE
    Biologicals; 2010 Jan; 38(1):144-9. PubMed ID: 19783458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
    Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
    Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
    Fan D; Li Z; Zhang X; Yang Y; Yuan X; Zhang X; Yang M; Zhang Y; Xiong D
    J Hematol Oncol; 2015 Feb; 8():18. PubMed ID: 25879549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Most immature T-ALLs express Ra-IL3 (CD123): possible target for DT-IL3 therapy.
    Lhermitte L; de Labarthe A; Dupret C; Lapillonne H; Millien C; Landman-Parker J; Hermine O; Baruchel A; Sigaux F; Macintyre E; Asnafi V
    Leukemia; 2006 Oct; 20(10):1908-10. PubMed ID: 16900212
    [No Abstract]   [Full Text] [Related]  

  • 14. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression.
    Testa U; Riccioni R; Biffoni M; Diverio D; Lo-Coco F; Foà R; Peschle C; Frankel AE
    Blood; 2005 Oct; 106(7):2527-9. PubMed ID: 15928038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia.
    Hall PD; Virella G; Willoughby T; Atchley DH; Kreitman RJ; Frankel AE
    Clin Immunol; 2001 Aug; 100(2):191-7. PubMed ID: 11465948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia.
    Kiyokawa T; Shirono K; Hattori T; Nishimura H; Yamaguchi K; Nichols JC; Strom TB; Murphy JR; Takatsuki K
    Cancer Res; 1989 Jul; 49(14):4042-6. PubMed ID: 2786749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies.
    Williams MD; Rostovtsev A; Narla RK; Uckun FM
    Protein Expr Purif; 1998 Jul; 13(2):210-21. PubMed ID: 9675065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein.
    Alexander RL; Kucera GL; Klein B; Frankel AE
    Bioconjug Chem; 2000; 11(4):564-8. PubMed ID: 10898579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor.
    Frankel AE; Ramage J; Kiser M; Alexander R; Kucera G; Miller MS
    Protein Eng; 2000 Aug; 13(8):575-81. PubMed ID: 10964987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells.
    Feuring-Buske M; Frankel A; Gerhard B; Hogge D
    Exp Hematol; 2000 Dec; 28(12):1390-400. PubMed ID: 11146161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.